CT MRI LI-RADS in Routine Practice

Abstract

Primary liver cancer is the third most common cause of cancer-related deaths worldwide with hepatocellular carcinoma (HCC) comprising the vast majority of the cases. HCC unlike most solid cancers can be diagnosed based on imaging findings alone using multiphasic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) without the need for histopathological confirmation in the majority of the cases. Liver Imaging Reporting and Data System (LI-RADS) was first introduced by the American College of Radiology in 2011 with the help of a multidisciplinary team of liver disease experts to improve the accuracy, consistency, and clarity of communication of imaging findings between radiologists and treating physicians. To date, LI-RADS has undergone four major updates in 2013, 2014, 2017, and 2018. This article reviews the technical aspects, categorization, and major and ancillary imaging features for the application of LI-RADS version 2018 using CT and MRI in routine clinical practice.

Keywords

APHE - CT - LI-RADS - LR-TR - MRI

Publikationsverlauf

Artikel online veröffentlicht:
31. August 2023

• References

• 1 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology 2020; 72 (05) 1605-1616
• 2 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020
• 3 Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR guidelines imaging criteria in HCC diagnosis using MRI with hepatobiliary contrast agents. BioMed Res Int 2018; 2018: 7465126
• 4 Marks RM, Masch WR, Chernyak V. LI-RADS: past, present, and future, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol 2021; 216 (02) 295-304
• 5 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
• 6 Schwarze V, Marschner C, Völckers W. et al. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020; 48 (06) 300060520930151
• 7 Chernyak V, Fowler KJ, Kamaya A. et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018; 289 (03) 816-830
• 8 Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR. Differences in Liver Imaging and Reporting Data System categorization between MRI and CT. AJR Am J Roentgenol 2016; 206 (02) 307-312
• 9 Kambadakone AR, Fung A, Gupta RT. et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. [published correction appears in Abdom Radiol (NY). 2018 Jan;43(1):240] Abdom Radiol (NY) 2018; 43 (01) 56-74
• 10 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273 (01) 30-50
• 11 Krishan S, Dhiman RK, Kalra N. et al. Joint consensus statement of the Indian National Association for study of the liver and Indian radiological and imaging association for the diagnosis and imaging of hepatocellular carcinoma incorporating liver imaging reporting and data system. J Clin Exp Hepatol 2019; 9 (05) 625-651
• 12 American College of Radiology website. CT/MRI Liver Imaging Reporting and Data System version 2018. . Available at: Zugriff am 22. August 2023 unter: www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018
• 13 Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS^® algorithm: CT and MRI. Abdom Radiol (NY) 2018; 43 (01) 111-126
• 14 Choi JY, Cho HC, Sun M, Kim HC, Sirlin CB. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR Am J Roentgenol 2013; 201 (05) 993-1001
• 15 Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 2018; 43 (01) 149-157
• 16 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021; 46 (12) 5723-5734
• 17 Tang A, Bashir MR, Corwin MT. et al; LI-RADS Evidence Working Group. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018; 286 (01) 29-48
• 18 International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49 (02) 658-664
• 19 Kielar AZ, Chernyak V, Bashir MR. et al. LI-RADS 2017: an update. J Magn Reson Imaging 2018; 47 (06) 1459-1474
• 20 Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002; 12 (04) 753-764
• 21 Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY) 2018; 43 (01) 75-81
• 22 Cerny M, Chernyak V, Olivié D. et al. LI-RADS version 2018 ancillary features at MRI. Radiographics 2018; 38 (07) 1973-2001